Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthis Synofzik

Showing results (201-210 of 511) with videos related to

Pageof 52
Sort By:
Neurology|January 2, 2024
Clinical, Imaging, Genetic, and Disease Course Characteristics in Patients With GM2 Gangliosidosis: Beyond Age of OnsetJan Kern, Judith Böhringer, Dagmar Timmann, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 21, 2024
FARS-ADL across Ataxias: Construct Validity, Sensitivity to Change, and Minimal Important ChangeAndreas Traschütz, Zofia Fleszar, Holger Hengel, et al.
Acta Neuropathologica|November 28, 2025
A new FTLD-TDP subtype with annexin A11 co-pathologyManuela Neumann, Marleen Van den Broeck, Sarah Wynants, et al.
Brain : a Journal of Neurology|April 26, 2022
The prodromal phase of hereditary spastic paraplegia type 4: the preSPG4 cohort studyTim W Rattay, Maximilian Völker, Maren Rautenberg, et al.
Frontiers in Neurology|July 6, 2019
Effects of Exergaming on Attentional Deficits and Dual-Tasking in Parkinson's DiseaseEva Schaeffer, Jan-Hinrich Busch, Benjamin Roeben, et al.
American Journal of Human Genetics|May 26, 2026
Guidance on communication and informed consent with patients and their families for experimental individualized treatmentsAnnemieke Aartsma-Rus, Claudio M de Gusmao, Scott Demarest, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 5, 2025
A Pharmacometrics-Informed Trial Simulation Framework for Optimizing Study Designs for Disease-Modifying Treatments in Rare Neurological DisordersYevgen Ryeznik, Ralf-Dieter Hilgers, Nicole Heussen, et al.
European Journal of Neurology|November 1, 2021
Effects of exergaming on hippocampal volume and brain-derived neurotrophic factor levels in Parkinson's diseaseEva Schaeffer, Benjamin Roeben, Oliver Granert, et al.
Parkinsonism & Related Disorders|December 8, 2018
The movement disorder spectrum of SCA21 (ATX-TMEM240): 3 novel families and systematic review of the literatureAndreas Traschütz, Judith van Gaalen, Mayke Oosterloo, et al.
Brain : a Journal of Neurology|November 22, 2012
S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathwayKinnari Sathe, Walter Maetzler, Johannes D Lang, et al.
Pageof 52

Showing results (201-210 of 511) with videos related to

Sort By:
Pageof 52
Neurology|January 2, 2024
Clinical, Imaging, Genetic, and Disease Course Characteristics in Patients With GM2 Gangliosidosis: Beyond Age of OnsetJan Kern, Judith Böhringer, Dagmar Timmann, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 21, 2024
FARS-ADL across Ataxias: Construct Validity, Sensitivity to Change, and Minimal Important ChangeAndreas Traschütz, Zofia Fleszar, Holger Hengel, et al.
Acta Neuropathologica|November 28, 2025
A new FTLD-TDP subtype with annexin A11 co-pathologyManuela Neumann, Marleen Van den Broeck, Sarah Wynants, et al.
Brain : a Journal of Neurology|April 26, 2022
The prodromal phase of hereditary spastic paraplegia type 4: the preSPG4 cohort studyTim W Rattay, Maximilian Völker, Maren Rautenberg, et al.
Frontiers in Neurology|July 6, 2019
Effects of Exergaming on Attentional Deficits and Dual-Tasking in Parkinson's DiseaseEva Schaeffer, Jan-Hinrich Busch, Benjamin Roeben, et al.
American Journal of Human Genetics|May 26, 2026
Guidance on communication and informed consent with patients and their families for experimental individualized treatmentsAnnemieke Aartsma-Rus, Claudio M de Gusmao, Scott Demarest, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 5, 2025
A Pharmacometrics-Informed Trial Simulation Framework for Optimizing Study Designs for Disease-Modifying Treatments in Rare Neurological DisordersYevgen Ryeznik, Ralf-Dieter Hilgers, Nicole Heussen, et al.
European Journal of Neurology|November 1, 2021
Effects of exergaming on hippocampal volume and brain-derived neurotrophic factor levels in Parkinson's diseaseEva Schaeffer, Benjamin Roeben, Oliver Granert, et al.
Parkinsonism & Related Disorders|December 8, 2018
The movement disorder spectrum of SCA21 (ATX-TMEM240): 3 novel families and systematic review of the literatureAndreas Traschütz, Judith van Gaalen, Mayke Oosterloo, et al.
Brain : a Journal of Neurology|November 22, 2012
S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathwayKinnari Sathe, Walter Maetzler, Johannes D Lang, et al.
Pageof 52